Initiation of antiretroviral therapy in the hospitalized patient with an acute AIDS-related opportunistic infection and other conditions: No time to lose
Purchase on Springer.com
$39.95 / €34.95 / £29.95*
Rent the article at a discountRent now
* Final gross prices may vary according to local VAT.
Treatment guidelines have recently become more definitive regarding the optimal timing for initiation of combination antiretroviral therapy (ART) in the setting of an acute AIDS-related opportunistic infection (OI). These recent changes reflect new data from a prospective, randomized study and several retrospective studies, all of which support earlier initiation of ART during an OI. These studies focus on OIs for which effective antimicrobial therapy exists. For AIDS-related conditions that lack effective antimicrobial therapy, there are few studies to help inform the optimal timing to initiate ART, but most clinicians initiate ART early, as little else can be offered to these patients. For patients with HIV admitted for non-AIDS-related conditions, there are few data that directly address the optimal timing for ART. Initiating ART in the hospitalized patient can be challenging and requires a well-coordinated multidisciplinary team with expertise in ART management.
- Mocroft A, Vella S, Benfield TL, et al.: Changing patterns of mortality across Europe in patients infected with HIV-1. EuroSIDA Study Group. Lancet 1998, 352:1725–1730. CrossRef
- Palella FJJ, Delaney KM, Moorman AC, et al.: Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med 1998, 338:853–860. CrossRef
- Buchacz K, Baker RK, Moorman AC, et al.: Rates of hospitalizations and associated diagnoses in a large multisite cohort of HIV patients in the United States, 1994–2005. AIDS 2008, 22:1345–1354. CrossRef
- Recommendations of the National Institutes of Health, the Centers for Disease Control and Prevention, and the HIV Medicine Association of the Infectious Diseases Society of America: Guidelines for prevention and treatment of opportunistic infections in HIV-infected adults and adolescents. June 18, 2008. Available at http://aidsinfo.nih.gov/content-files/Adult_OI.pdf. Accessed November 18, 2008.
- Gazzard BG on behalf of the BHIVA Treatment Guidelines Writing Group: British HIV Association guidelines for the treatment of HIV-1-infected adults with antiretroviral therapy 2008. HIV Med 2008, 9:563–608. CrossRef
- Dean GL, Edwards SG, Ives NJ, et al.: Treatment of tuberculosis in HIV-infected persons in the era of highly active antiretroviral therapy. AIDS 2002, 16:75–83. CrossRef
- Shelburne SA, Visnegarwala F, Darcourt J, et al.: Incidence and risk factors for immune reconstitution inflammatory syndrome during highly active antiretroviral therapy. AIDS 2005, 19:399–406. CrossRef
- Zolopa A, Anderson J, Komarow L, et al.: Immediate vs. deferred ART in the setting of an acute AIDS-related opportunistic infection: final results of a randomized strategy trial, ACTG 5164. Presented at the 15th Conference on Retroviruses and Opportunistic Infections. Boston, MA; February 3–6, 2008.
- Breton G, Duval X, Estellat C, et al.: Determinants of immune reconstitution inflammatory syndrome in HIV type-1 infected patients with tuberculosis after initiation of antiretroviral therapy. Clin Infect Dis 2004, 39:1709–1712. CrossRef
- Ratnam I, Chiu C, Kandala NB, Easterbrook PJ: Incidence and risk factors for immune reconstitution inflammatory syndrome in an ethnically diverse HIV type 1-infected cohort. Clin Infect Dis 2006, 42:418–427. CrossRef
- Murdoch DM, Venter W, Feldman C, Van Rie A: Incidence and risk factors for the immune reconstitution inflammatory syndrome in HIV patients in South Africa: a prospective study. AIDS 2008, 22:601–610. CrossRef
- Park WB, Choe PG, Jo JH, et al.: Immune reconstitution inflammatory syndrome in the first year after HAART: influence on long-term clinical outcome. AIDS 2006, 20:2390–2392. CrossRef
- Centre for the AIDS Programme of Research in South Africa: Press Release—Important New Research Findings on Treatment of TB-HIV Co-Infection. Available at http:// www.caprisa.org. Accessed November 12, 2008.
- ClinicalTrials.Gov. Available at http://clinicaltrials. gov/ct2/results?term=tuberculosis+AND+HIV. Accessed December 2, 2008.
- Morris A, Wachter RM, Luce J, et al.: Improved survival with highly active antiretroviral therapy in HIV-infected patients with severe Pneumocystis carinii pneumonia. AIDS 2003, 17:73–80. CrossRef
- Bisson GP, Nthobatsong R, Thakur R, et al.: The use of HAART is associated with decreased risk of death during initial treatment of cryptococcal meningitis in adults in Botswanna. J Acquir Immune Defic Syndr 2008, 49:227–229. CrossRef
- May M, Sterne JA, Sabin C, et al.: Prognosis of HIV-1-infected patients up to 5 years after initiation of HAART: collaborative analysis of prospective studies. AIDS 2007, 21:1185–1197. CrossRef
- Strategies for Management of Antiretroviral Therapy (SMART) Study Group, El-Sadr WM, Lundgren JD, et al.: CD4+ count-guided interruption of antiretroviral treatment. N Engl J Med 2006, 355:2283–2296. CrossRef
- Panel on Antiretroviral Guidelines for Adults and Adolescents: Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services. November 3, 2008; 1–139. Available at http://www.aidsinfo.nih.gov/ContentFiles/ AdultandAdolescentGL.pdf. Accessed November 18, 2008.
- Hammer SM, Eron JJ Jr, Reiss P, et al.: Antiretroviral treatment of adult HIV infection: 2008 recommendations of the International AIDS Society-USA panel. JAMA 2008, 300:555–570. CrossRef
- Giardi E, Sabin S, Monforte A: Late diagnosis of HIV infection: epidemiological features, consequences and strategies to encourage earlier testing. J Acquir Immune Defic Syndr 2007, 46:S3–S8. CrossRef
- Sabin CA, Smith CJ, Gumley H, et al.: Late presenters in the era of highly active antiretroviral therapy: uptake of and responses to antiretroviral therapy. AIDS 2004, 18:2145–2151. CrossRef
- Chadborn TR, Baster K, Delpech VC, et al.: No time to wait: how many HIV-infected homosexual men are diagnosed late and consequently die? (England and Wales, 1993–2002). AIDS 2005, 19:513–520. CrossRef
- Murri R, Ammassari A, Trotta M, et al.: Patient-reported and physician-estimated adherence to HAART: social and clinic center-related factors are associated with discordance. J Gen Intern Med 2004, 19:1104–1110. CrossRef
- Ammassari A, Trotta MP, Murri R, et al.: Correlates and predictors of adherence to highly active antiretroviral therapy: overview of published literature. J Acquir Immune Defic Syndr 2002, 31:S123–S127.
- Howard AA, Arnsten JH, Lo Y, et al.: A prospective study of adherence and viral load in a large multi-center cohort of HIV-infected women. AIDS 2002, 16:2175–2182. CrossRef
- Gardner EM, Sharma S, Peng G, et al.: Differential adherence to combination antiretroviral therapy is associated with virological failure with resistance. AIDS 2008, 22:75–82. CrossRef
- National HIV/AIDS Clinicians’ Consultation Center: Dosage form modifications and renal/hepatic dosing of antiretrovirals. Available at http://www.nccc.ucsf. edu/Clinical_Resources/Pharmacy/PDFs/4-07 HIV Dosage Table.pdf. Accessed November 18, 2008.
- Huang L, Quartin A, Jones D, Havlir DV: Intensive care of patients with HIV infection. N Engl J Med 2006, 355:173–181. CrossRef
- Kitahata MM, Koepsell TD, Deyo RA, et al.: Physicians’ experience with the acquired immunodeficiency syndrome as a factor in patients’ survival. N Engl J Med 1996, 334:701–706. CrossRef
- Bennett CL, Garfinkle JB, Greenfield S, et al.: The relation between hospital experience and in-hospital mortality for patients with AIDS-related PCP. JAMA 1989, 261:2975–2979. CrossRef
- Sax PE, Islam R, Walensky RP, et al.: Should resistance testing be performed for treatment-naive HIV-infected patients? A cost-effectiveness analysis. Clin Infect Dis 2005, 41:1316–1323. CrossRef
- Weinstock HS, Zaidi I, Heneine W, et al.: The epidemiology of antiretroviral drug resistance among drug-naive HIV-1-infected persons in 10 US cities. J Infect Dis 2004, 189:2174–2180. CrossRef
- Novak RM, Chen L, MacArthur RD, et al.: Prevalence of antiretroviral drug resistance mutations in chronically HIVinfected, treatment-naive patients: implications for routine resistance screening before initiation of antiretroviral therapy. Clin Infect Dis 2005, 40:468–474. CrossRef
- Wensing AM, van de Vijver DA, Angarano G, et al.: Prevalence of drug-resistant HIV-1 variants in untreated individuals in Europe: implications for clinical management. J Infect Dis 2005, 192:958–966. CrossRef
- Wheeler W, Mahle K, Bodnar U, et al.: Antiretroviral drug-resistance mutations and subtypes in drug-naïve persons newly diagnosed with HIV-1 infection, US, March 2003 to October 2006. Presented at the 14th Conference on Retroviruses and Opportunistic Infections. Los Angeles, CA; February 25–28, 2007.
- Gallant JE, DeJesus E, Arribas JR, et al.: Tenofovir DF, emtricitabine, and efavirenz vs. zidovudine, lamivudine, and efavirenz for HIV. N Engl J Med 2006, 354:251–260. CrossRef
- Ribaudo HJ, Kuritzkes DR, Lalama CM, et al.: Efavirenz-based regimens in treatment-naive patients with a range of pretreatment HIV-1 RNA levels and CD4 cell counts. J Infect Dis 2008, 197:1006–1010. CrossRef
- Initiation of antiretroviral therapy in the hospitalized patient with an acute AIDS-related opportunistic infection and other conditions: No time to lose
Current HIV/AIDS Reports
Volume 6, Issue 2 , pp 63-67
- Cover Date
- Print ISSN
- Online ISSN
- Current Science Inc.
- Additional Links